The U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to a promising new treatment for dry age-related macular degeneration (AMD)—a leading cause of vision loss.
The therapy is being developed by Luxa Biotechnology and supported in part by the California Institute for Regenerative Medicine (CIRM).
What RMAT Designation Means
RMAT designation goes to regenerative medicine therapies that show strong early results in treating serious conditions like dry AMD. It allows the FDA to work closely with developers to speed up clinical trials and the approval process, helping new treatments reach patients sooner.
A New Approach to Treating Dry AMD
Dry AMD affects nearly 20 million people in the United States. The disease develops when cells in the macula—the part of the retina responsible for sharp vision—gradually deteriorate, leading to vision loss.
Luxa’s therapy aims to replace these damaged cells. Researchers grow retinal pigment epithelial (RPE) cells in the lab and transplant them into the retina to restore function. These cells support photoreceptors, which detect light and make vision possible.
Clinical Trial Progress
Dr. Jeffery Stern, Luxa’s Chief Medical Officer, leads the Phase 1/2a clinical trial. The trial is supported by a $4 million CIRM grant and additional funding from the National Eye Institute.
Dr. Stern will present Phase 1 data at the Wills Eye Conference in Philadelphia on March 6, 2025.
Early clinical results helped secure the RMAT designation, highlighting the therapy’s potential to address the unmet needs of patients with dry AMD, who currently have few treatment options.
Why This Matters
If successful, this cell‑based therapy could become a new regenerative treatment for AMD, offering hope to millions at risk of vision loss. The RMAT designation shows that the FDA sees strong potential in this approach and is prioritizing its development.
CIRM has invested more than $200 million in vision research, including several AMD therapy programs, underscoring its commitment to advancing treatments for blindness and vision impairment.
“Luxa’s therapy shows potential in restoring lost vision in patients with dry AMD,” said Joseph Gold, PhD, Senior Director of Clinical Development at CIRM.
This is the first CIRM‑funded clinical trial for dry AMD to receive RMAT designation.
Related Posts
Advancing cell therapy research for dry age-related macular degeneration
CIRM-funded study helps unlock some of the genetic secrets behind AMD
Stem cell stories that caught our eye: new CRISPR fix for sickle cell
Oh wow, great new, I wish this could help me regain my vision… I had an accident and damaged my left eye.. the doctor said it’s a scar on the retinal and nothing can’t done to regain my vision… I can only very blurry on the left eye.. my right eye is good, Thank God! 🙏